Press Releases

Enlyton LLC retains Biotech Alliances International Inc. to Lead $15m Series A Capital Raise

ENL210 is a disruptive opportunity to improve the care of patients with colon cancer, and to extend the science of Immuno-Oncology to the surgical arena.”

— Wayne Poll, MD, CEO

October 8, 2018, SAN FRANCISCO, CALIFORNIA , SAN MATEO,  /EINPresswire.com/ — Biotech Alliances International, a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Enlyton LLC for its Series A $15m capital raise.

Enlyton, LLC., an Ohio, USA early-stage biotech company has developed a molecular biomarker for colon cancer, and other solid cancers.

Molecular markers to improve the care of patients with certain cancers is a developing and highly valued clinical opportunity, but as yet, there are no markers available for colon cancer, one of the most common cancers worldwide.

Enlyton has developed an antibody fragment, ENL210, that attaches to a tumor antigen, TAG-72, which will allow for the precise imaging, surgical localization, and complete removal of colon cancer.

ENL210 is a disruptive opportunity to improve the care of patients with colon cancer, and to extend the science of Immuno-Oncology to the surgical arena.

“Surgeons at Ohio State University have previously used a predecessor monoclonal antibody to localize and remove all TAG-72 antigen in over 1,200 patients with cancer”, said Wayne Poll MD, CEO of Enlyton. “Those patents whom had all TAG-72 tissue removed enjoyed a significantly improved 15-year survival compared to standard of care surgery”.

“This financing will help Enlyton to complete the manufacturing of the molecule and to perform Phase I/II human trials”, said Franck Brinkhaus, CEO of Biotech Alliances International. We are very excited to work with the Enlyton team on this assignment.

About Biotech Alliances International Inc.

Biotech Alliances International Inc. is a San Francisco-based investment bank serving life sciences companies, private equity and venture capital funds. It provides independent financial and strategic advice including corporate finance, mergers & acquisitions, partnering & licensing, deal sourcing and strategic consulting.

Dr. Franck Brinkhaus
Biotech Alliances International INC
(1) 650 868 8511

 
International Investments Launch Development of Ohio-Based Novel Cancer Agent 
 
 January 1, 2018 COLUMBUS, Ohio, – Enlyton, Ltd., a Columbus, Ohio, company developing innovative oncology products, has signed an agreement for a series of investments by East Sunshine Foresight Fund, the venture capital arm of HEC Pharm of Shenzen, China. The financing supports the development of ENL210, a bioengineered monoclonal antibody fragment that targets the broad family of solid tumors known as adenocarcinomas.
 
ENL210 is the product of years of basic and clinical research, primarily in Ohio, and will enable oncologists to more accurately locate and precisely treat adenocarcinomas of the colon, pancreas, lung breast, prostate, and other organs. There are approximately 850,000 new cases of adenocarcinoma annually in the United States, and over 7 million worldwide, representing about 70% of all solid tumors.
 
Enlyton’s co-founder Edward W. Martin, Jr., M.D., is a surgical oncologist with over 40 years of experience treating adenocarcinomas. “The HEC investment is critically important to moving the ENL210 project forward. While years of research have taught us that accurate targeting and subsequent removal of this class of solid tumors results in better outcomes, we believe ENL210 will make it practical in today’s clinical setting,” Martin said. “ENL210 is an important addition to the emerging science and clinical application of immuno-oncology.”
ENL210 employs a commonly used radionuclide of iodine, enabling surgeons to identify and remove even small sites of cancer intra-operatively. Martin stated, “Published studies indicate that this more precise approach to tumor removal remarkably improves surgical outcomes.”
 
Lester Johnson, M.D., Ph.D., FACR, a diagnostic radiologist and expert in molecular imaging added, “Physicians who diagnose and treat solid tumors have long sought better ways to assess the extent of disease and monitor the effectiveness of treatments in their patients more accurately. Enlyton’s new agent (ENL210) has the potential to make a significant difference for these patients and their physicians, and I look forward to reviewing the clinical study data that will soon emerge.”
“ENL210 works by selectively binding with high affinity to the well- known adenocarcinoma marker TAG-72,” said Thomas Magliery, Ph.D., Enlyton’s Chief Scientific Officer and the architect of ENL210. “TAG-72 is consistently expressed by nearly 85% of all adenocarcinoma tumors, and not expressed in non-cancerous tissue, so it is an ideal marker to locate cancerous tissue that can be very hard to find. ENL210 has been engineered to find TAG-72 safely and produce high-contrast images in a short time.”
 
Enlyton’s Chief Executive Officer, Wayne Poll, M.D., a urological oncologist added, “On behalf of the entire Enlyton team, I want to thank the leadership at HEC for their confidence in our science and our management team. We will soon initiate final development including GMP manufacturing, pre-clinical toxicology studies, IND submission, and our first clinical trial. We will require additional funding to complete all this work, but clearly, the promise of significantly better outcomes for many hundreds of thousands of cancer patients worldwide is a cause we all can champion.”
 
About Enlyton, Ltd. 
Enlyton is integrating proprietary antibody technology into cancer-specific, antigen-directed targeting agents for use in cancer imaging, intraoperative cancer detection, and post-operative disease prognosis. Enlyton’s goal is to provide more accurate disease information, enabling oncologists to personalize each patient’s course of therapy, reduce the overall cost of cancer treatment, and most importantly save lives.
 
About HEC 
HEC Pharm is a holding company owned by HEC Group, one of the top 100 private enterprises in China, which in 2016 exceeded RMB 30 billion in revenue. HK HEC Pharm (1558.HK), a part of HEC Pharm, focused on the domestic medicine business, is listed on Hong Kong Stock Exchange. HEC Tech (SS.600673), another company holding by HEC Group, is a listed company on the Shanghai Stock Exchange. Since established in 2002, HEC Pharm has made over USD 1.6 billion in R&D capital investment and over the past three years the annual R&D budget has exceeded USD 150 million. HEC R&D Center is developing new molecular entities, generics and biosimilars in several therapeutic areas, as anti-virus, oncology, diabetes, and neurology. HEC set up 2 national labs for drug research and discovery by the State. More information about HEC Pharm is available at www.hecpharm.com.
 
DISCLOSURE NOTICE: The information contained in this release is as of Dec. 20, 2017. Enlyton assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This press release contains forward-looking information about Enlyton’s development and clinical applications of its oncology imaging and detection business, including, without limitation, the potential benefits and timing thereof, and about the outlook and potential opportunities for its product(s). The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” ”believe,” and “confident” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve considerable risks and uncertainties that could cause actual results to differ substantially from those expressed or implied by such statements. Risks and uncertainties include, but are not limited to, lack of adequate capital, the possibility that the Company may not be able to consummate, at all or within the specified time period, any successful development of its product(s) that may result from production, market, regulatory and other factors; that unpredictable variables exist that are fundamental in business operating and financial performance, including, but not limited to, competitive developments and general economic, political, business, industry, regulatory and other market conditions; future exchange and interest rates; and changes in tax and other laws, regulations, rates and policies. Enlyton’s products are not currently available for sale and have not been approved by the U.S. Food and Drug Administration or any country’s regulatory authority
 

Enlyton, Ltd. Awarded National Cancer Institute SBIR Phase I Contract for Tumor Targeting Agent for SPECT Imaging of Cancer

September 2012 COLUMBUS, Ohio – Enlyton, Ltd., a technology leader in the development of cancer-specific tumor targeting agents for use in molecular imaging, has been awarded a   Phase I Small Business Innovation Research (SBIR) contract in the amount of $249,525 from the National Cancer Institute (NCI). The Phase I contract, which will cover approximately 10% of the total project cost, will be used to complete pre-clinical development of Enlyton’s antibody-based tumor targeting agent for SPECT imaging of adenocarcinomas (e.g., colorectal, esophageal, stomach, lung, ovarian, pancreatic).

Current cancer imaging and detection methods often fail to provide a clear picture of the extent of disease. SPECT (single photon emission computed tomography) is a sizeable market with a large base of installed scanners that has not been adequately supported for use in cancer imaging. Recent developments, e.g., SPECT/CT (computed tomography) fused imaging technology with attenuation correction, have improved SPECT performance and its clinical relevance for cancer imaging. The work of this contract will construct an antibody-based targeting agent that can rapidly accumulate in tumors while clearing from circulation quickly, and enable dosing and imaging within 24 hours using existing SPECT and SPECT/CT imaging platforms.

“Funding from this NCI SBIR contract will enable Enlyton, in collaboration with development partners Applied Biomolecular Technologies, Quanta BioDesign, and The Ohio State University, to complete this effort, and initiate the production of clinical grade antibody in the third quarter 2013”, added Enlyton CEO Jeff Bergen.

About Enlyton, Ltd.

Enlyton is integrating proprietary antibody technology into cancer-specific, antigen-directed targeting agents for use in cancer imaging, intraoperative cancer detection, and post-operative disease prognosis. Enlyton’s goal is to provide more accurate disease information, enabling oncologists to better determine the course of therapy, save lives, and reduce the overall cost of cancer treatment.

 

Fifteen Year Data Shows TAG-72 Antigen is a Major Factor in Patient Survival

July 2011 COLUMBUS, Ohio — Enlyton, Ltd., announced the publication of a 15-year follow-up analysis of long-term cancer survival comparing the presence or absence of tumor associated glycoprotein–72 (TAG-72) in patients after undergoing antigen-directed cancer surgery for colorectal cancer. TAG-72 is a shed tumor antigen that is produced by adenocarcinoma cells and accumulates in and around cancerous tissues.

The study concluded that the absence of detectable TAG-72 antigen within the surgical field at completion of antigen-directed cancer surgery for primary colorectal cancer is of significant prognostic value, conferring a long-term survival advantage to those in whom complete surgical removal of all tissues with detectable radiolabeled anti-TAG-72 uMAb was accomplished.

Dr. Edward W. Martin Jr. (Enlyton CSO and Professor of Surgery at The Ohio State University) added, “We are excited with the conclusiveness of the data and the proof it demonstrates for continuing our development of TAG-72 based approaches for targeting cancer.”

The study, entitled, “Antigen-Directed Cancer Surgery for Primary Colorectal Cancer: 15-Year Survival Analysis” was published in the Annals of Surgical Oncology (DOI 10.1245/s10434-011-1880-3) by Povoski, Hatzaras, Mojzisik, Arnold, Hinkle, Hitchcock, Young, and Martin, authors from The Ohio State University and Enlyton, Ltd.

 

ViroMed and Enlyton Sign Licensing Agreement to Develop Humanized Antibody to TAG-72 for Cancer Detection

February 2011 SEOUL, KOREA  – ViroMed Co., Ltd. (KOSDAQ: 084990), a leading biotechnology company, announced that the company has entered into a licensing agreement with Enlyton, Ltd., an Ohio-based company developing improved methods of molecular imaging.

The agreement grants Enlyton exclusive worldwide rights to develop 3E8, a humanized monoclonal antibody (mAb) designed to target the tumor-associated glycoprotein 72 (TAG-72) antigen, for use in cancer detection and targeted drug delivery. Under the terms of the agreement Enlyton will pay ViroMed an upfront licensing fee with milestone payments totaling $4.7 million, and additional royalty payments based on revenues.

“We are pleased to have entered into an agreement with Enlyton, an up-and-coming company in the field of cancer detection,” said Paul Kim, Vice President of Business Development at ViroMed. “As the development time of antibodies for detection is comparatively faster than that of therapeutic antibodies, we expect to be able to enter this $8 billion dollar industry much sooner. This agreement is another important step in establishing ViroMed as a leading biotech company in Asia.” Enlyton CEO Jeff Bergen added, “This agreement provides Enlyton with access to an antibody that has been shown to offer great promise for use in cancer imaging and detection.”

About 3E8 3E8 is a humanized monoclonal antibody (mAb) designed to target the tumor associated glycoprotein 72 (TAG-72) antigen. TAG-72 is highly expressed (50-90%) in various epithelial derived cancers such as colonic adenocarcinomas, invasive ductal breast carcinomas, non-small cell lung carcinomas, epithelial ovarian carcinomas, and most pancreatic, gastric, and esophageal cancers. In preclinical testing, 3E8 showed a higher affinity to TAG-72 and had a lower immune response compared with previous TAG-72-specific mAb diagnostic imaging agents.

About ViroMed

ViroMed Co., Ltd. is a leading biotechnology company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus: DNA/protein-based biopharmaceuticals and phytotherapeutics (botanical drugs/nutraceuticals). ViroMed now has five main products in its pipeline targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials ongoing in the US, Korea, and China. To learn more about the company and its products, visit www.viromed21.com.

 

New Data from Enlyton Supports Use of an Antigen-Directed, Cancer-Specific Targeting Agent for PET-Based Imaging
September 2010 COLUMBUS, Ohio  — Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton’s antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer. In the study, Enlyton’s targeting agent increasingly localized in tumor, while 18F-FDG did not. 18F-FDG also exhibited the tendency to localize in normal tissues. Dr. Edward Martin Jr. (Enlyton CSO and Professor of Surgery at The Ohio State University) said, “We are excited with the results of the study and the potential it offers for successful use of our cancer-specific targeting agent in clinical trials for preoperative, intraoperative, and postoperative PET-based imaging of colorectal cancer.”

The study, entitled, “124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results,” was published in the World Journal of Surgical Oncology (2010, 8:65) by Zou, Povoski, Hall, Carlton, Hinkle, Xu, Mojzisik, Johnson, Knopp, Martin, and Sun, authors from Enlyton, Ltd., The Ohio State University, and The University of Michigan. (View the whole article at http://wjso.com/content/8/1/65.)